275 results about "Phospholipid complex" patented technology

The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano: phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided.

A Resveratrol-phospholipid complex, process for the preparation of same and relating highly bioavailable antioxidant and radical blocking pharmaceutical compositions, and cosmetic compositions for the treatment of ageing and cellular degeneration.

The invention relates to a herba epimedii aglycone phospholipid compound or a cyclo-herba epimedii aglycone phospholipid compound, which is characterized by being composed of herba epimedii aglycone or cyclo-herba epimedii aglycone and phospholipid, wherein the mass ratio of the herba epimedii aglycone or the cyclo-herba epimedii aglycone and the phospholipid is 1:0.5 to 5. The phospholipid in theherba epimedii aglycone phospholipid compound or the cyclo-herba epimedii aglycone phospholipid compound has the positive function on treating the osteoporosis, and the medicine and the phospholipidin the phospholipid compound of the herba epimedii aglycone or cyclo-herba epimedii aglycone medicine has the synergic function on treating the osteoporosis; after the phospholipid and the herba epimedii aglycone or the cyclo-herba epimedii aglycone are prepared into the compound, the dissolvability thereof is improved greatly, and the disadvantages of poor water solubility and fat solubility andlow bioavailability are solved; the herba epimedii aglycone phospholipid compound or the cyclo-herba epimedii aglycone phospholipid compound has simple preparation process and moderate reaction condition, and is suitable to industrialized big production. The invention discloses a preparation method thereof.

The invention provides a silybin and phosphatidy lcholine compound which is prepared into capsules with high dissolving degree. The invention also provides a process for preparing the silybin and phosphatidy lcholine compound and its capsule medicament, the preparing process is characterized by simple manufacturing method, high yield and fitting for mass production.

The present invention relates to an oral formulation comprising a hyaluronic acid-phospholipid complex, and to use of a hyaluronic acid-phospholipid complex for the manufacture of a joint function-improving and protecting agent for oral administration which can alleviate the arthritic symptoms in patients with arthritic conditions, increase the concentration of hyaluronic acid in synovial fluid, improve the lubrication of joints, as well as maintain and enhance the normal functions of joints.

The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor / phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.

The invention relates to resveratrol phosphatide compound, the preparation method and its applciaiton. The resveratrol mainly comprises stilbenes parent nucleus, and is slightly soluble or insoluble in water, and is not stable. So the biological utilization rate is low and medical effect is reduced and the parenteral administration is limited. The key is to increase its solubility, so the resveratrol phosphatide compound is needed by market. The resveratrol phosphatide compound comprises resveratrol and phosphatide, with the weight proportion being 1: 0.5-50.The product can be used to prepare tablet, capsule, granule, suppository, injection, or freeze dried or compound tablet.

Phosphatidylserine is extracted from animal brains by: drying animal brains, smashing them into granules, putting propanone into the granules, stirring and extracting, separating propanone supernatant liquid contained cholesterine and oils from the brain granules, steaming the residues to be dried, adding n-hexane or alcohol or ammonia water alcohol into steamed dry residues, stirring and extracting, separating extracting liquid contained phospholipid compositions, steaming the residues again, putting ether into steamed dry residues, stirring, freezing and defreezing, filtering to remove deposits, removing the remained phospholipid further, adjusting supernatant liquid pH=3-6, steaming to remove ether, and steaming to dry crude phosphatidylserine again, dissolving crude phosphatidylserine dry powders in n-hexane, adding sodium acetate alcohol liquid, stirring, settling to be laminated, removing the supernatant contained inositol phospholipid, finally, steaming to dry the n-hexane in supernatant liquid to obtain high pure phosphatidylserine under reduced pressure.

The present invention discloses phosphatide composition of active skullcap components and its preparation. The active skullcap components are prepared through extracting and separating skullcap root, and contain baicalin or wogonin over 50 %. The active skullcap components have low water solubility and fat solubility, solubility increasing with raised solution pH value, and easy chemical degradation in alkaline condition, so that the active skullcap components can not be prepared into injection and oral preparation directly. By means of phosphatide composition technology, the present invention improves the water dispersivity and lipophilicity of the active skullcap components, so as to prepare oral preparation with high bioavailability, freeze dried powder for injection, fat emulsion and mucous membrane administration preparation.

The present invention relates to novel phospholipids complexes of curcumin or extracts containing it having improved bioavailability.

The invention relates to a medicine technical field. Etoposide has broad-spectrum anticancer activity and rather high therapeutic index, however, the etoposide hardly can be dissolved in water and the fat-soluble property is rather poor, the shortcoming of low bioavailability exists to different extent in oral preparations for present clinical use, tablet and soft capsule, for example. The invention aims at improving the hydrophilic property and the lipotropy of the etoposide, promoting the bioavailability of the etoposide and providing an etoposide preparation which has a simple preparation technique and is easily taken. Main medicine of the preparation of the invention is phospholipid compound of etoposide. The invention also provides a self-emulsifying agent and a preparation method thereof. The zooperies is a primary indication that the ACU of the self-emulsifying agent of the phospholipid compound of etoposide is 1.3 to 1.7 times of that of the soft capsules on sale.

The invention provides a glycyrrhetic acid and phospholipid composites of glycyrrhetate and process for preparing same by forming phospholipid compound in suitable dissolvent from glycyrrhizinic acid and its salts with a definite quantity of lecithin, thus converting the physical and chemical property, and improving the bioavailability of the glycyrrhizic acid and its salts.

The invention relates to an NRP-1 ligand polypeptide-polyethylene glycol-phosphatide compound, an active targeting liposome drug delivery system mediated thereby and a preparation method thereof. A carrier system comprises; a. phosphatide; b. cholesterol; c. methoxy polyethylene glycol-phosphatide compound; and d. polypeptide-polyethylene glycol-phosphatide compound containing an RPARPAR sequence. The above components are in a molar ratio of: a:b=5:1-1:5, a:c=1000:0.1-1000:100, and a:d=1000:0.1-1000:100. The system can carry out intravenous route drug administration and target the drug to a tumour position according to tumour EPR effect and RPARPAR mediation effect. The liposome drug delivery system can be applied to tumour diagnosis or targeting delivery of a treatment medicament.

A nano-class suspension injection of oxaliplatin-phoshpatide composition for intravenous injection is proportionally prepared from oxaliplatin, surfactant, pH regulator, isotonic agent, antioxidant, water for injection, and optional excipient (for the freeze-dried powder injection).

The invention relates to a method for preparing a dual-function targeting quantum dot lipidosome. The method comprises the following steps: preparing a single quantum dot lipidosome: dissolving phospholipid, cholesterol, methoxy polyethylene glycol-phospholipid complex and NRP-1 ligand polypeptide polyethylene glycol phospholipid complex into chloroform to obtain a uniform lipid membrane, and drying the chloroform by evaporation; dissolving in an ammonium sulfate solution of quantum dots, and oscillating to obtain lipidosome suspension; extruding, and diluting with normal saline to obtain an active targeting lipidosome containing the quantum dots; adding the active targeting lipidosome containing the quantum dots into an adriamycin normal saline solution, and treating in a water bath for 20 minutes at the temperature of 60 DEG C; and diluting with normal saline through a SephadexG-50 gel column, removing free medicaments, and thus obtaining the dual-function targeting quantum dot lipidosome. The lipidosome prepared by the method can be used for marking and treating glioma cells.

The invention belongs to the technical field of medicine and discloses a preparation method of sub-microemulsion used for the intravenous injection of polyene yew alcohol phospholipid composite. The sub-microemulsion of the polyene yew alcohol phospholipid composite is basically prepared from polyene yew alcohol, phospholipid, liquid oil, a surfactant, cholesterol, a cholesterol derivative, or / and a similar cholesterol derivative, an addition agent and water for injection according to the effective therapeutic dose. The sub-microemulsion of the polyene yew alcohol phospholipid composite provided by the invention has high medicine carrying quantity and good preparation stability; and the preparation method is simple, convenient and easy and is easy for realizing industrialization.

The invention discloses a ginsenoside Rg 3 and phospholipid complex and a preparing method thereof, belonging to the filed of medicines and health care products. The components comprise ginsenoside Rg 3 and phospholipid, and the mol ratio of the ginsenoside Rg 3 to the phospholipid is 1 : 1 to 10. The preparing method adopts organic solvent with small dielectric constant to dissolve the mixture of the ginsenoside Rg 3 and the phospholipid, and then the ginsenoside Rg 3 and phospholipid complex is prepared after the technical processes of solvent evaporation and the like. The ginsenoside Rg 3 and phospholipid complex has fat solubility and high bioavailability, and can be easily absorbed by human bodies and made into preparations such as emulsion and the like.

The invention discloses an anthocyanin phospholipids compound and a preparation method thereof, comprises an anthocyanin phospholipids compound and a preparation method thereof, and belongs to the field of medicaments and health-care products. The components of the anthocyanin phospholipids compound comprise anthocyanin and phospholipids, wherein the weight ratio of the anthocyanin to the phospholipids is 1:1-20; and the preparation method adopts an organic solvent with a small dielectric constant for dissolving a mixture of the anthocyanin and the phospholipids and prepares the anthocyanin phospholipids compound through solvent evaporation and other technical processes. The anthocyanin phospholipids compound has the advantages of lipid solubility, easy absorption, high bioavailability, emulation formulation, and the like.

The invention discloses a phospholipid complex albumin nanoparticle containing epipodophyllotoxins medicine. The nanoparticle contains a complex formed by epipodophyllotoxins medicine and phospholipid and albumin. The nanoparticle comprises the following raw materials in parts by weight: 1 part of epipodophyllotoxins medicine, 1-50 parts of phospholipid and 2-100 parts of albumin. The phospholipid complex albumin nanoparticle can be used for remarkably reducing the toxicity of the epipodophyllotoxins medicine, especially bone marrow suppression; meanwhile, the phospholipid complex albumin nanoparticle has liver-lung targeting property.

The invention discloses a nano-suspension for a silybin-phospholipid complex and a preparation method thereof, wherein the nano-suspension for a silybin-phospholipid complex is prepared by combining a technology of promoting medicine absorption by a phospholipid complex with a solubilizing-targeting technology of nano-suspension; the ingredients of the nano-suspension for silybin-phospholipid complex comprise a silybin-phospholipid complex, a stabilizer and water; the nano-suspension exists in the form of suspension or freeze-dried powder and prepared by combining a microprecipitation method with a high-pressure homogenization method; the method of the invention prepares a nano-suspension hard to dissolve in a medicine, without a need to pre-micronize raw material medicines, which greatly decreases energy consumption; the grain diameter distribution range of the prepared nano-grains is narrow, and the medicine highly disperses in a granular state, which increases the wettability, solubility and solution velocity of the medicine, thereby improving the oral bioavailability thereof; the technique process of the preparation method is simple and easy to realize industrial production.

The invention discloses a baicalein phospholipid complex and a preparation method thereof. The baicalein phospholipid complex is compounded by baicalein and phospholipid, wherein the weight ratio of the baicalein to the phospholipid is 1:1-6. The invention also discloses a preparation method of the baicalein phospholipid complex. The baicalein phospholipid complex prepared by the invention can improve the hydrophilicity and lipophilicity of the baicalein, and improve the bioavailability of the baicalein.

The present invention relates to a neuropilin-1 ligand polypeptide-polyethylene glycol-phospholipid composite, its active targeting liposome vector system and a preparation method thereof. The liposome vector system comprises the following components: a: phospholipid, b: cholesterol, c: methoxy polyethylene glycol-phospholipid composite (with the molecular weight of methoxy polyethylene glycol ranging from 400 to 6000), and d: a RPAKPAR sequence-containing polypeptide-polyethylene glycol-phospholipid composite (with the molecular weight of polyethylene glycol ranging from 400 to 8000). And for the components, a and b are in a molar ratio of 5:1-1:5, a and c are in a molar ratio of 1000:1-1000:100, and a and d are in a ratio of 1000:0.1-1000:100. The system can make a liposome passively drained into a lymphatic system through subcutaneous interstitial injection or intramuscular injection, and can make the liposome targeted to a lymphatic metastasis lesion through the mediation effect of RPAKPAR. The system can also make the liposome targeted to a primary tumor and a hematogenous metastasis lesion directly through intravenous injection administration, through a tumor EPR (electron paramagnetic resonance) effect and the mediation effect of RPAKPAR. The liposome vector system of the invention can be used for targeted drug delivery in diagnosis or treatment of prostate cancer primary tumors and metastatic tumors.

The invention discloses a cefixime capsule and a preparation method thereof. The preparation is prepared by uniformly mixing dry particles and talcum powders, and filling the mixture into a capsule shell, wherein the dry particles are prepared by uniformly mixing cefixime phospholipid complex containing silicon dioxide, a filler and a disintegrating agent, through dry granulating; and in the cefixime phospholipid complex containing silicon dioxide, the weight ratio of the cefixime to the phospholipid to the silicon dioxide is 1: (1-3): (0.2-0.8). The cefixime capsule prepared by the invention is strong in stability, high in dissolution degree and simple in production process.

The invention discloses a preparation method of resveratrol phospholipid complex self-microemulsion particles. The method comprises the following steps: fully mixing and dissolving a surfactant, caprylic / capric triglyceride and a co-emulsifier at 40-60 DEG C to obtain a blank self-microemulsion; adding a resveratrol phospholipid complex into the blank self-microemulsion, and uniformly stirring to obtain a resveratrol self-microemulsion; adding hydroxypropyl methyl cellulose into the resveratrol self-microemulsion, and uniformly stirring to obtain a suspended resveratrol self-microemulsion; and adding microcrystalline cellulose to ensure that the resveratrol self-microemulsion is transformed into solid-state granular powder so as to obtain a product. By virtue of the mode, the preparation method of the resveratrol phospholipid complex self-microemulsion particles, disclosed by the invention, is simple, and does not need special high-energy-consumption production equipment in a preparation process; and the obtained product can be used for effectively improving the solubility of resveratrol in water and improving the influences of stomach dispersing and intestinal steatolysis, and is high in biological effective availability.

The invention discloses a preparation method of a curcumin and phospholipid complex and relates to the technical field of medicines and preparation thereof. The curcumin and phospholipid complex is prepared by compounding curcumin and phospholipid; the invention further discloses the preparation method of the curcumin and phospholipid complex and dissolution performance of the curcumin and phospholipid complex; the curcumin and phospholipid complex prepared by the preparation method can be used for improving the hydrophily and lipophilicity of the curcumin and improving the bioavailability of the curcumin.

The invention discloses a Cabazitaxel phospholipid complex and a method for preparing a lipid microsphere injection which contains the phospholipid complex. The lipid microsphere injection consists of Cabazitaxel, injection phospholipid, injection oil, an emulsifying agent, a stabilizing agent, an antioxidant, an isoosmotic adjusting agent and water for injection. The lipid microsphere injection has the characteristics of high drug-loading rate, slow releasing, small adverse reaction, simplicity and practicability in preparation technology, good product stability and the like and is beneficial to clinic application and industrial production.

A method for treating valvular stenosis The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal Most preferred is an Apolipoprotein A-1 mimetic peptide / phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

The invention discloses a novel insulin-phospholipid-chitosan self-assembled microparticle carrier and a drug delivery system thereof, wherein the mass ratio of insulin to phospholipid is 1 to (3-100); and the mass ratio of chitosan to the phospholipid is 1 to (5-50). The self-assembled microparticle carrier disclosed by the invention is prepared by preparing an insulin-phospholipid compound from the insulin and a proper amount of the phospholipid material in a special environment, injecting a non-aqueous solvent organic phase of the insulin-phospholipid compound to an aqueous-phase solution of the chitosan, and self-assembling in a warm stirring condition, so that the insulin-phospholipid-chitosan microparticle carrier is formed. The insulin-phospholipid-chitosan microparticle carrier disclosed by the invention is free from the addition of a cross-linking agent, is represented in a circular or elliptic form and has a multilayer capsule structure; the grain size distribution of the microparticle carrier is 50-5000nm and a drug entrapment rate reaches 70% or above; the microparticle carrier is good in quality stability in a gastrointestinal fluid environment and low in burst release; the microparticle carrier can break through the limitation of an enzyme barrier and a membrane barrier; and the microparticle carrier is used for preparing insulin non-injection drug delivery systems such as oral drug delivery, mucosal drug delivery, percutaneous drug delivery and the like.

The invention discloses a medicinal composition containing silybin dihemisuccinate disodium and a preparation method and application thereof. Silybin dihemisuccinate disodium and phospholipid are dissolved into an organic solvent according to a certain proportion, and a product is obtained by heating reflux, drying and concentration. The composition increases the dissolution of silybin, improves the lipid solubility, and obviously solves the problem of low bioavailability of the silybin. The composition has the effect of protecting liver, and can be used for treating acute or chronic hepatitis, fatty liver and other liver function injury.